Recent Headlines
Microvascular Therapeutics Has Received Funds from the National Heart, Lung and Blood Institute (NHLBI)
Microvascular Therapeutics (MVT) has received funds from the from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health for its program to treat cardiovascular disease, which kills more Americans than any other disease. As a leader in fluorocarbon... - July 19, 2021 - Microvascular Therapeutics, Inc.
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old
Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccines for cancer and infectious diseases where the active... - July 14, 2021 - Mirror Biologics, Inc.
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer
Mirror Biologics, Inc. (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ cancer vaccines in which the active ingredients are living... - July 09, 2021 - Mirror Biologics, Inc.
Parvus Therapeutics Announces CEO, Senior Executive, and Board of Directors Appointments
Appoints CEO, Senior Executive, and Board of Directors: Peter M. Strumph, Chief Executive Officer; Brendan Classon PhD, Executive Vice President, Research and Development; Louis Demers, Vice President of Technical Operations; Matthew J. Hogan, member of the Board of Directors - July 06, 2021 - Parvus Therapeutics U.S., Inc.
GRG Announces 2021 Regenerative Medicine Congress in Dubai UAE
The 2nd Global Regenerative Medicine Congress will be held in Dubai 9-11 September 2021. Registration is now open. Global Regenerative Academy is a world-renowned medical society scientifically studying the clinical application of biological products in the human body. Regenerative Medicine treatments using biological products have been used to slow down the natural aging process, treat a variety of pathologies and improve the quality of life of patients. - June 28, 2021 - Global Regenerative Group
Paras Biopharmaceuticals Finland Oy Named as One of the Top Pharma Outsourcing Companies in Europe 2021
Paras Biopharmaceuticals Highlights Company Innovations that Decode and Create Biologics Medicines for Unmet Medical Needs (Pharma Tech Outlook, USA) - June 22, 2021 - Paras Biopharmaceuticals Finland Oy
Canada’s Leader in Cannabis Genetics Enters Medical Market
Apollo Green, Canada’s leader in cannabis genetics, announced its entry into the medical marijuana sales with unique strains of cannabis not commonly available in the Canadian marketplace. The importance of having available alternatives for pain management cannot be understated. Studies have recently shown the link between cannabis availability and reduced use of opioids. Three specialty strains of plants and seven strains of seeds will be available in Ontario, Canada. - June 08, 2021 - Apollo Green
Updated Findings of COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing Report
2021 Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing and Changes Since 2020 - May 25, 2021 - Life Science Strategy Group, LLC
Advanced Silicon Group Closes Seed Preferred Equity Offering and Adds Alan Watson and Sarah Kelly to Board
Advanced Silicon Group, Inc. (ASG), a pioneer in silicon nanotechnology focused on developing novel biosensors, announced today the closing of a $1,020,000 seed preferred stock offering led by Cherrystone Angel Group with participation by MIT Alumni Angels of Northern California, Sidecar Angels and other private investors and the addition of two new Directors, Alan Watson, PhD, MBA and Sarah Kelly, PhD to its Board of Directors. - May 16, 2021 - Advanced Silicon Group
Cayman Develops Powerful, New Multiplex ELISA for Autoantibody Detection
Cayman Chemical's new Q-Plex™ Autoantibody Detection 10-Plex Panel, developed in collaboration with Quansys Biosciences, offers standardized, multiplex capabilities for the concurrent analysis of ten prominent analytes associated with rheumatoid arthritis or other autoimmune diseases. This... - May 16, 2021 - Cayman Chemical Company
CNS Healthcare Announces Launch of eReg Platform, Making Access to Regulatory Documents Available from Virtually Anywhere at Any Time
CNS Healthcare announced today the launch of eReg, an electronic regulatory binder platform. This first of its kind, web-based application will essentially replace paper binders and allow for remote monitoring capability. The proprietary platform developed by CNS Healthcare CIO & CISO, Florin... - May 14, 2021 - CNS Healthcare
Paras Biopharmaceuticals Finland Oy is Named as One of the Top 30 Admired Companies to Watch 2021
Paras Biopharmaceuticals Finland Oy, a fast-growing, biopharmaceutical technology development company, based in Oulu, Finland, announced today that it is named as one of the top 30 admired companies to watch during 2021, by CIO Bulletin, USA. - April 28, 2021 - Paras Biopharmaceuticals Finland Oy
Courage Therapeutics Awarded STTR Grant to Design Novel Anorexia Drugs
Courage Therapeutics has been awarded an STTR grant by the National Insittute of Mental Health to design novel anorexia drugs. The grant is a follow-up to research by the Cone lab at the University of Michigan that recently published in Science Translational Research that MC3R is a potential target for therapeutic development in anorexia and obesity. The effort allows for an expeditious translation of basic science into eating disorders which have remained an area of significant unmet need. - April 23, 2021 - Courage Therapeutics
Courage Therapeutics Raises $1M for Treatment of Anorexia Nervosa and Other Related Eating Disorders
Courage Therapeutics raised $1M towards development of treatments for eating disorders including Anorexia Nervosa, ARFID, BED and genetic obesity. The company is led by Dan Housman a parent of children with eating disorders. The round was led by Michigan Biomedical Ventures. Funding will be used to test Courage’s proprietary compounds in animal models of eating disorders. The technology is based on the research on MC3R at the University of Michigan from co-founder Dr. Roger Cone’s lab. - March 24, 2021 - Courage Therapeutics
Eurofins Viracor BioPharma Launches PanCancerIQ Comprehensive Genomic Profiling Service to Advance Precision Oncology Clinical Drug Development
Eurofins Viracor BioPharma Services, a global leader in specialty bioanalytical testing services, announces the launch of their new PanCancerIQ genomic profiling test; a next-generation sequencing (NGS) service that enables comprehensive genomic profiling of tumor samples. In addition to expanding... - March 11, 2021 - Eurofins Viracor BioPharma
Stargardt Disease - MD Stem Cells New Treatment Improves Vision
Stem Cell Ophthalmology Treatment Study (SCOTS) show positive results in 84% of eyes. - February 18, 2021 - MD Stem Cells
Paras Biopharmaceuticals Finland Oy Affordable Healthcare Efforts Viewed in Over 90 Countries: Biosimilar Technologies Get Attention
Paras Biopharmaceuticals Finland Oy (Paras Biopharma) is a Finland-based microbial biologics company which focuses on the development of technologies for biosimilars and biologics in an efficient manner. The overall objective of Paras Biopharma is to enable economical production and future availability of affordable medicines for unmet medical needs. - February 17, 2021 - Paras Biopharmaceuticals Finland Oy
Cayman Adds Nordic BioSite as Trusted Distributor
Cayman Chemical’s complete assay kit, protein, antibody, and biochemical portfolio is now more accessible to Denmark, Finland, Iceland, Norway, Sweden, and the Baltic countries as well as Russia through a distribution agreement with Nordic BioSite. Headquartered in Täby, Sweden, Nordic... - February 10, 2021 - Cayman Chemical Company
Kevin Sarney Joins Charles River CFO to Lead Life Sciences Practice
Charles River CFO, Inc. (CRCFO), a provider of part-time and interim CFO and accounting services, today announced Kevin Sarney has joined the leadership team as the Life Sciences Practice Leader and CFO. With over 20 years of experience in public and private life sciences companies, Kevin will lead... - January 21, 2021 - Charles River CFO
NuvOx Pharma Announces Appointment of Jon S. Saxe to Its Board of Directors
NuvOx Pharma today announced that Jon S. Saxe has joined its Board of Directors. Saxe brings to NuvOx many years of experience from the biotechnology, pharmaceutical and venture capital industries. He has served as a director of more than 25 companies and currently is a director of several... - December 28, 2020 - NuvOx Pharma
GRG Announces Partnership with BPB Medica
The Global Regenerative Group and BPB Medica(TM) Italy are very pleased to announce a global consultancy relationship to further develop the distribution of BPB Medica(TM) products. - December 02, 2020 - Global Regenerative Group
Cayman Breaks Ground on State-of-the-Art Facility Projecting Future Growth in R&D
Cayman held a groundbreaking ceremony to start the buildout of a $20 million research and development facility at its headquarters in Ann Arbor, MI. - November 07, 2020 - Cayman Chemical Company
Adeoye Olukotun, M.D., MPH, FACC Joins Evon Medics, LLC as Advisor
Small business, Evon Medics, LLC today announced that pharmaceutical luminary and cardiologist, Dr. Adeoye Olukotun has joined the advisory board of the company in a formal advisory role. Dr. Olukotun is currently the Chief Executive Officer of CR Strategies, LLC, which consults on clinical trial... - November 01, 2020 - Evon Medics, LLC
Volasertib, a Potential New Treatment for Rhabdomyosarcoma, Receives Orphan Drug Designation from the U.S. FDA
Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to volasertib for its use in treating pediatric rhabdomyosarcoma and other rare soft tissue sarcomas. Key... - October 15, 2020 - Oncoheroes Biosciences Inc.
3Sixty Pharma Solutions Announces Successful Approval of FDA Investigational New Drug Application
3Sixty Pharma Solutions LLC., www.3sixtypharma.com, has announced the successful submission to FDA, and approval of, an Investigational New Drug (IND) Application on behalf of one of its clinical-stage biotech clients. 3Sixty Pharma Solutions’ 360 Start-Up arm continues to be committed to... - October 15, 2020 - 3Sixty Pharma Solutions
Evon Medics, LLC Has Been Awarded $1.7 Million Grant for the Evaluation of Its Medical Device for the Treatment of Opioid Use Disorder
Small business, Evon Medics, LLC today announced that it has been awarded a non-dilutive grant of $1.7 million for its Phase II SBIR (Small Business Innovation Research) clinical trials for the development and evaluation of its non-invasive Chemosensory-Based Orbitofrontal Cortex Training (CBOT)... - October 11, 2020 - Evon Medics, LLC
Cayman Receives SBIR Grant for Alzheimer’s Research
The National Institute on Aging (NIA) has awarded Cayman Chemical with a Phase II Small Business Innovation Research (SBIR) grant to develop an assay platform and novel antibodies to support the treatment, prevention, and early diagnosis of Alzheimer’s disease and other tauopathies. - October 10, 2020 - Cayman Chemical Company
FDA Grants Rare Pediatric Disease Designation (RPDD) to Volasertib for Rhabdomyosarcoma
Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, is pleased to announce that the United States Food and Drug Administration (FDA) has granted the designation of rare pediatric disease to volasertib, an investigational treatment for rhabdomyosarcoma. Key... - September 25, 2020 - Oncoheroes Biosciences Inc.
Paras Biopharmaceuticals Finland Oy Joins PSL Alliance and Its Global Membership to Promote Worldwide Reach Out for Paras’ Bioprocess Enzymes
Paras Biopharmaceuticals Finland Oy (Paras Biopharma) is pleased to announce that it is now a member of the Pivotal Scientific Limited (PSL) Alliance, a network of companies operating within the biotechnology market. As part of the Company’s portfolio of microbial products, technologies and... - September 08, 2020 - Paras Biopharmaceuticals Finland Oy
3 Bros Grow Vertically Integrated Sustainable Cannabis Facility
3 Bros Grow announces sustainable vertically integrated cannabis cultivation, manufacturing, processing and distribution. - August 27, 2020 - 3 Bros Grow
New eClinical Platform Strategic Analysis & Competitive Landscape Report
Survey Quantifies eClinical Platform Use and Satisfaction and Identifies Dramatic Perceptual Changes - August 26, 2020 - Life Science Strategy Group, LLC
Grants Available for Undergraduate Students Seeking Research Experience
Cayman Biomedical Research Institute (CABRI) is now accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted until September 20, 2020, for awards to be distributed by November 2, 2020. Grants range from $2,000 - $5,000 and may be awarded as individual or group grants. - August 19, 2020 - Cayman Chemical Company
Cayman and GenScript Partner to Offer Neoantigen Profiling and Synthesis Expertise
Cayman and GenScript have come together to create a complete package of neoantigen discovery services. Through combined efforts, MHC-associated peptides are identified and verified as immunogenic to guide peptide synthesis for vaccine development. “Cayman provides a complete workflow enabling... - August 15, 2020 - Cayman Chemical Company
New Study Highlights Exciting Potential of Umbilical Cord Tissue to Treat COVID-19
COVID-19 patients administered with Mesenchymal Stromal Cells (MSCs) from cord tissue all recover from disease. - Cord tissue cells shown to promote tissue repair and regeneration and support normal function of immune system. - Insception Lifebank is Canada’s first and largest cord blood... - August 07, 2020 - Insception
Microvascular Therapeutics Receives NIH SBIR Phase I Funds for Its Alzheimer Program
Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Institute of Aging (NIA), part of the National Institutes of Health (NIH). Wyatt Unger, MD, MBA, President and CEO of MVT said,... - August 03, 2020 - Microvascular Therapeutics, Inc.
Microvascular Therapeutics Receives NIH SBIR Phase I Funds for Its Program to Treat Heart Attack
Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health. Wyatt Unger, MD, MBA, President and CEO of... - July 31, 2020 - Microvascular Therapeutics, Inc.
3 Bros Grow Announces Vertically Integrated Cannabis Genetics Nursery
The 3 Bros Grow, a vertically integrated cannabis company, is moving into their first phase of greenhouse nursery to provide clean secured genetics, clones and teens to their operations. Luck #7, Cherry Bomb, Twizzlas, Grease Monkey and Chocolatina are some of the exclusive genetics available only from 3 Bros Grow. - July 01, 2020 - 3 Bros Grow
40 Women Researchers Receive $40,000 in Grants from Cayman and CABRI
Each year during Women’s History Month, Cayman provides travel grants to help women researchers attend conferences to benefit from and contribute to the larger scientific community. This year, because the COVID-19 pandemic caused most conferences to cancel or postpone and many academic labs to close, Cayman introduced a new program to help support women in research. A record high of forty women will benefit from Cayman’s Women in Research program this year. - July 01, 2020 - Cayman Chemical Company
R3 International Now Offering Stem Cell Therapy for Coronavirus in Mexico
R3 Stem Cell International is now offering stem cell therapy for coronavirus patients at its first rate Center in Tijuana, Mexico. Several treatment options are available that include up to 200 million stem cells, with pricing starting at only $2975. A growing body of research out of Europe,... - June 30, 2020 - R3 Stem Cell
AdvantaPure(R) Now Offers GORE(R) STA-PURE(R) Pump Tubing, an Industry Staple for Single-Use Biotech and Pharmaceutical Processes
AdvantaPure is now a systems integrator of GORE STA-PURE Pump Tubing, Series PCS. The AdvantaPure team is expert at molding connections for tubing assemblies and can overmold GORE STA-PURE Pump Tubing as the pump element in biopharm and pharmaceutical assemblies. The overmolding process results in a smooth contact surface for optimal fluid flow. GORE STA-PURE Pump Tubing connects to any of AdvantaPure’s AdvantaSil(R) platinum-cured silicone tubing using overmolding technology. - June 17, 2020 - AdvantaPure
Zeteo Biomedical Introduces ZEOx1 AquilaMD™ Ophthalmic Drug Delivery System
Zeteo’s patient-centric ophthalmic delivery systems are designed for precise, self-administration of preservative free drugs and biopharmaceuticals. - June 01, 2020 - Zeteo Biomedical LLC
Experimentica Ltd. Announces the Successful Acquisition of the Ophthalmic Contract Research Division from Ophthy-DS, Inc.
Experimentica Ltd., a leader in preclinical ophthalmic drug discovery services, announces the successful acquisition of the contract research division from Ophthy-DS, Inc., a Michigan-based preclinical contract research organization (CRO) specializing in non-regulated drug discovery services and medical device testing for ophthalmic indications. - May 22, 2020 - Experimentica Ltd
Zeteo Biomedical Receives NIH Award to Develop a Universal Nasal Flu Vaccine in Collaboration with the Iowa State University Nanovaccine Institute
Vaccines that can be quickly manufactured, deployed and self-administered at global scale volumes is crucial to protect global populations against pandemic virus threats. - May 20, 2020 - Zeteo Biomedical LLC
Zeteo Biomedical Introduces ZEOx1 Orion(TM) Nasal Vaccine and Drug Delivery Systems
Zeteo’s patient-centric delivery systems are designed for quick manufacturing to facilitate rapid deployment of drugs and vaccines to global populations. - May 14, 2020 - Zeteo Biomedical LLC
New COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing Report
Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing - April 30, 2020 - Life Science Strategy Group, LLC
Virun and East West Bank Partner-Up to Save Lives
VIRUN Nutra-biosciences was able to get fully funded with the help of East West Bank. VIRUN manufactures food products and dietary supplements and are considered part of the essential workforce. Virun makes immune boosting products such as liposomal Vitamin C and patented, clinically proven Glutathione Tripeptides bound to Lactoferrin that have shown success in trials toward innate immunity. - April 22, 2020 - VIRUN
3 Bros Grow Announces Compassion Program During COVID-19
The 3 Bros Santa Cruz dispensary is currently running a compassion program during the COVID-19 outbreak and Shelter in Place orders. As an essential business and being allowed to remain open to serve the community for cannabis products such as cannabis flower, pre-rolls, edibles, topicals and... - April 18, 2020 - 3 Bros Grow
New Treatment Shows Vision Benefit in Age Related Macular Degeneration
MD Stem Cells reports results for Dry AMD from their clinical study SCOTS - the Stem Cell Ophthalmology Treatment Study. 63% of treated and evaluated eyes achieved improvement in vision while an additional 34% had vision remain stable in follow up. No complications occurred. Results were statistically significant. - April 18, 2020 - MD Stem Cells
Aciont's Paper, "Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules" Published in JOPT
Aciont Inc. announced today that results from preclinical studies of its Visulex-I technology is published online ahead of print in the Journal of Ocular Pharmacology and Therapeutics under the title “Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of... - April 18, 2020 - Aciont Inc.
Cellix Bio Pharma Initiates Acquisition of Avaca Pharma: Formulation Development CRO
Cellix Bio Pharma, a global contract research organization (CRO), transforms today’s healthcare challenges into tomorrow’s solutions. Cellix Bio Pharma is an experienced CRO focused on development of pharmaceutical formulations. Cellix Bio Pharma focuses to combine the AI computational power to the chemical and biological space in order to streamline drug discovery, design, development, and optimization that can expedite drug development. - April 10, 2020 - Cellix Bio Pharma Private Limited